

South & Central America Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

<https://marketpublishers.com/r/SAA9BA9022C2EN.html>

Date: January 2026

Pages: 209

Price: US\$ 3,450.00 (Single User License)

ID: SAA9BA9022C2EN

Abstracts

The South & Central America Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US\$ 1,094.6 million by 2031, up from US\$ 248.9 million in 2024, with an estimated compound annual growth rate (CAGR) of 25.4% from 2025 to 2031.

Executive Summary and Market Analysis

The anti-obesity drugs market in South & Central America is divided into key regions: Brazil, Argentina, and the Rest of South & Central America. The market is expanding due to increasing obesity rates, heightened health awareness, and improved access to healthcare services. Factors such as sedentary lifestyles and changing dietary habits have led to a rise in obesity, prompting governments and health organizations to focus on weight management initiatives. Urbanization and economic growth have enhanced healthcare infrastructure and the availability of pharmaceutical products. Public health campaigns and media efforts have also contributed to reducing the stigma associated with obesity, encouraging more individuals to seek medical treatment. The introduction of innovative anti-obesity drugs, particularly GLP-1 receptor agonists, has further increased interest among patients and confidence among healthcare providers. Additionally, the rise of medical tourism in certain countries is making the region a destination for affordable treatments. These elements are collectively driving market growth and attracting investments from major pharmaceutical companies eager to meet the rising demand.

Strategic Insights

Market Segmentation Analysis

By Type: The market is categorized into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.

By Mechanism of Action: Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.

By Drug Class: Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominated the market in 2024.

By GLP-1 Agonist: Further divided into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide having the largest share in 2024.

By Application: Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading in 2024.

By Route of Administration: The market is segmented into Oral and Parenteral, with Oral being the most prevalent in 2024.

By Distribution Channel: Includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies holding the largest share in 2024.

Market Outlook

Emerging economies present significant opportunities for the anti-obesity drugs market, driven by rising obesity rates linked to urbanization and lifestyle changes. The enhancement of healthcare infrastructure and increased awareness of obesity-related health risks are fueling demand for effective treatments. Pharmaceutical companies are investing in these markets to address the unmet need for weight management solutions. Brazil, for instance, is improving its healthcare infrastructure and obesity management programs, creating a favorable environment for new anti-obesity medications. In April 2024, Brazil inaugurated a laboratory in Hortolândia, São Paulo, dedicated to producing diabetes and obesity medications, including liraglutide and semaglutide, with an investment of R\$60 million (~US\$ 10.93 million).

While initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments, future insurance coverage and the introduction of generic

versions in middle-income countries are expected to enhance accessibility. The increasing prevalence of obesity in emerging economies, combined with expanding healthcare infrastructure and growing awareness, is driving demand for anti-obesity drugs. Government initiatives and pharmaceutical investments are fostering a conducive environment for market growth, positioning emerging markets as key areas for expansion in the South & Central America anti-obesity drugs market.

Country Insights

The South & Central America Anti-Obesity Drugs Market is segmented by country into Brazil, Argentina, and the Rest of South & Central America, with the Rest of South & Central America holding the largest share in 2024. Notably, Chile, Colombia, Peru, and Bolivia are significant players in this market. Chile has the highest obesity rate in South America, with approximately 42% of adults classified as obese, projected to affect 14 million Chileans in the next five years. The rise in obesity is largely attributed to the availability of ultra-processed foods and sedentary lifestyles, leading to increased health issues such as type 2 diabetes and cardiovascular diseases.

Colombia has made significant healthcare reforms since the 1990s, resulting in approximately 97% of the population being covered under the social and health security system by 2023, facilitating greater access to obesity treatments and contributing to market growth.

Company Profiles

Key players in the South & Central America Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights
- 2.2 Market Attractiveness

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macroeconomic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country-level data:

4. ANTI-OBESITY DRUGS MARKET LANDSCAPE

- 4.1 Market Overview
- 4.2 PEST Analysis

5. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS

- 5.1 Market Drivers
- 5.2 Market Restraints
- 5.3 Market Opportunities
- 5.4 Future Trends
- 5.5 Impact of Drivers and Restraints:

6. ANTI-OBESITY DRUGS MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS

6.1 South & Central America Anti-Obesity Drugs Market Revenue (US\$ Million), 2024 - 2031

6.2 South & Central America Anti-Obesity Drugs Market Forecast and Analysis

7. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE

7.1 Prescription Drugs

7.1.1 Overview

7.1.2 Prescription Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

7.2 OTC Drugs

7.2.1 Overview

7.2.2 OTC Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION

8.1 Centrally Acting Drugs

8.1.1 Overview

8.1.2 Centrally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8.2 Peripherally Acting Drugs

8.2.1 Overview

8.2.2 Peripherally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8.3 Others

8.3.1 Overview

8.3.2 Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS

9.1 GLP-1 Agonist

9.1.1 Overview

9.1.2 GLP-1 Agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9.2 Lipase Inhibitors

9.2.1 Overview

9.2.2 Lipase Inhibitors: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9.3 MC4R agonist

9.3.1 Overview

9.3.2 MC4R agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9.4 Others

9.4.1 Overview

9.4.2 Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

10. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST

10.1 Semaglutide

10.1.1 Overview

10.1.2 Semaglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

10.2 Liraglutide

10.2.1 Overview

10.2.2 Liraglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

10.3 Tirzepatide (Zepbound)

10.3.1 Overview

10.3.2 Tirzepatide (Zepbound): South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION

11.1 Appetite Suppression

11.1.1 Overview

11.1.2 Appetite Suppression: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11.2 Inhibition of Fat Absorption or Digestive Enzymes

11.2.1 Overview

11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: South & Central America

Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11.3 Metabolic Enhancement

11.3.1 Overview

11.3.2 Metabolic Enhancement: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11.4 Combination

11.4.1 Overview

11.4.2 Combination: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

12. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION

12.1 Oral

12.1.1 Overview

12.1.2 Oral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

12.2 Parenteral

12.2.1 Overview

12.2.2 Parenteral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

13. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL

13.1 Hospital Pharmacies

13.1.1 Overview

13.1.2 Hospital Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

13.2 Online Channel

13.2.1 Overview

13.2.2 Online Channel: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

13.3 Retail Pharmacies

13.3.1 Overview

13.3.2 Retail Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET - COUNTRY

ANALYSIS

14.1 South & Central America

14.1.1 South & Central America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country

14.1.1.1 South & Central America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country

14.1.2.2 Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.1.2.2.1 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Type

14.1.2.2.2 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.1.2.2.3 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Drug Class

14.1.2.2.4 Brazil: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist

14.1.2.2.5 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Application

14.1.2.2.6 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration

14.1.2.2.7 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel

14.2.3.3 Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.2.3.3.1 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Type

14.2.3.3.2 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.2.3.3.3 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Drug Class

14.2.3.3.4 Argentina: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist

14.2.3.3.5 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Application

14.2.3.3.6 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration

14.2.3.3.7 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel

14.3.4.4 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.3.4.4.1 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Type

14.3.4.4.2 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.3.4.4.3 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Drug Class

14.3.4.4.4 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist

14.3.4.4.5 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Application

14.3.4.4.6 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration

14.3.4.4.7 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel

15 COMPETITIVE LANDSCAPE

15.1 Heat Map Analysis by Key Players

15.2 Company Positioning & Concentration

16 INDUSTRY LANDSCAPE

16.1 Overview

16.2 New Product Development

16.3 Merger and Acquisition

16.4 Other Strategic Developments

17 COMPANY PROFILES

17.1 GSK Plc

17.1.1 Key Facts

17.1.2 Business Description

17.1.3 Products and Services

17.1.4 Financial Overview

17.1.5 SWOT Analysis

17.1.6 Key Developments

17.2 F. Hoffmann-La Roche Ltd

- 17.2.1 Key Facts
- 17.2.2 Business Description
- 17.2.3 Products and Services
- 17.2.4 Financial Overview
- 17.2.5 SWOT Analysis
- 17.2.6 Key Developments
- 17.3 Teva Pharmaceutical Industries Ltd
 - 17.3.1 Key Facts
 - 17.3.2 Business Description
 - 17.3.3 Products and Services
 - 17.3.4 Financial Overview
 - 17.3.5 SWOT Analysis
 - 17.3.6 Key Developments
- 17.4 Novo Nordisk AS
 - 17.4.1 Key Facts
 - 17.4.2 Business Description
 - 17.4.3 Products and Services
 - 17.4.4 Financial Overview
 - 17.4.5 SWOT Analysis
 - 17.4.6 Key Developments
- 17.5 Eli Lilly and Co
 - 17.5.1 Key Facts
 - 17.5.2 Business Description
 - 17.5.3 Products and Services
 - 17.5.4 Financial Overview
 - 17.5.5 SWOT Analysis
 - 17.5.6 Key Developments
- 17.6 Sun Pharmaceutical Industries Ltd
 - 17.6.1 Key Facts
 - 17.6.2 Business Description
 - 17.6.3 Products and Services
 - 17.6.4 Financial Overview
 - 17.6.5 SWOT Analysis
 - 17.6.6 Key Developments
- 17.7 VIVUS LLC
 - 17.7.1 Key Facts
 - 17.7.2 Business Description
 - 17.7.3 Products and Services
 - 17.7.4 Financial Overview

- 17.7.5 SWOT Analysis
- 17.7.6 Key Developments
- 17.8 Currax Pharmaceuticals LLC.
 - 17.8.1 Key Facts
 - 17.8.2 Business Description
 - 17.8.3 Products and Services
 - 17.8.4 Financial Overview
 - 17.8.5 SWOT Analysis
 - 17.8.6 Key Developments
- 17.9 AdvaCare Pharma USA LLC
 - 17.9.1 Key Facts
 - 17.9.2 Business Description
 - 17.9.3 Products and Services
 - 17.9.4 Financial Overview
 - 17.9.5 SWOT Analysis
 - 17.9.6 Key Developments
- 17.10 Rhythm Pharmaceuticals Inc
 - 17.10.1 Key Facts
 - 17.10.2 Business Description
 - 17.10.3 Products and Services
 - 17.10.4 Financial Overview
 - 17.10.5 SWOT Analysis
 - 17.10.6 Key Developments

18. APPENDIX

- 18.1 About The Insight Partners

List Of Tables

LIST OF TABLES

- Table 1. South & Central America Anti-Obesity Drugs Market Segmentation
- Table 2. List of Vendors
- Table 3. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Table 4. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type
- Table 5. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action
- Table 6. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class
- Table 7. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist
- Table 8. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application
- Table 9. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration
- Table 10. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel
- Table 11. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Country
- Table 12. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type
- Table 13. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action
- Table 14. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class
- Table 15. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist
- Table 16. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application
- Table 17. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration
- Table 18. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel
- Table 19. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue

and Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 20. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 21. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 22. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 23. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 24. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 25. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 26. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 27. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 28. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 29. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 30. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 31. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 32. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 33. Heat Map Analysis by Key Players

List Of Figures

LIST OF FIGURES

- Figure 1. South & Central America Anti-Obesity Drugs Market Segmentation - Country
- Figure 2. PEST Analysis
- Figure 4. South & Central America Anti-Obesity Drugs Market - Key Market Dynamics
- Figure 5. Impact Analysis of Drivers and Restraints
- Figure 6. South & Central America Anti-Obesity Drugs Market Revenue (US\$ Million), 2024 - 2031
- Figure 7. South & Central America Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
- Figure 8. Prescription Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 9. OTC Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 10. South & Central America Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
- Figure 11. Centrally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 12. Peripherally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 13. Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 14. South & Central America Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
- Figure 15. GLP-1 Agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 16. Lipase Inhibitors: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 17. MC4R agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 18. Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 19. South & Central America Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
- Figure 20. Semaglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 21. Liraglutide: South & Central America Anti-Obesity Drugs Market - Revenue

and Forecast, 2021 - 2031 (US\$ Million)

Figure 22. Tirzepatide (Zepbound): South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 23. South & Central America Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031

Figure 24. Appetite Suppression: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 26. Metabolic Enhancement: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 27. Combination: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 28. South & Central America Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031

Figure 29. Oral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 30. Parenteral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 31. South & Central America Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031

Figure 32. Hospital Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 33. Online Channel: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 34. Retail Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 35. South & Central America Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)

Figure 36. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 37. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 38. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 39. Company Positioning & Concentration

I would like to order

Product name: South & Central America Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

Product link: <https://marketpublishers.com/r/SAA9BA9022C2EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SAA9BA9022C2EN.html>